Methods of immunosuppression comprising administering an anti-CD154 antibody
AssigneeImmunext, Inc.
InventorsJay Rothstein, Robert George Edward Holgate, Arron Hearn
Life of this patent
Estimating the term…
Abstract
Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.
Claims22
A method of immunosuppression or treatment of an allergic, inflammatory, or autoimmune disorder;
- or for eliciting prolonged antigen specific immunosuppression, or for treating or preventing graft versus host disease (GVHD), in a subject in need thereof comprising administering a therapeutically or immunosuppressive effective amount of an anti-CD154 antibody or antibody fragment which comprises a variable heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1 and a variable light chain polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2.
A method for treating a human condition, disorder or disease mediated in whole or in part by CD40 signaling, the method comprising administering an effective amount of an antibody or antibody fragment which comprises a variable heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1 and a variable light chain polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.